Lemtrada, manufactured by Genzyme (a Sanofi company), is a disease modifying therapy for people with relapsing-remitting forms of multiple sclerosis (RRMS). Biologically, it is a humanized monoclonal antibody aimed at specific receptors on the surface of immune cells to modulate immune responses. Although approved by the U.S. Food and Drug Administration (FDA), the agency recommends its use be restricted to RRMS patients who have had an inadequate response to two or more MS therapies.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?